Integrum (INTEG) Q3 24/25 earnings summary

Executive summary

• Strategic realignment focuses on accelerating U.S. growth, maintaining EU expansion, and leveraging technology leadership for bone-anchored prosthetic solutions.

• Shift prioritizes near-term U.S. revenue, cost control, and transparency with new KPIs, notably S1 surgeries.

• Management transition ongoing, with a search for a permanent CEO to drive commercialization and market adoption.

• Strategic shift includes cost efficiencies up to SEK 20 million annually and focus on centers of excellence.

• Directed share issue of SEK 31 million completed post-quarter to strengthen financial position.

Financial highlights

• Q3 net sales were SEK 23.7 million, down 21.2% year-over-year; nine-month net sales SEK 64.0 million, down 18.1%.

• U.S. sales stable at SEK 20.1 million; EMEA/APAC sales declined due to prior year Ukraine activities and distributor inventory buildup.

• Gross margin in Q3: 81%, consistent with historical levels but down from 90% prior year.

• EBIT/operating result: SEK -7.4 million in Q3 (vs. SEK 0.34 million prior year); nine-month operating result SEK -30.7 million.

• Cash flow for Q3: SEK -19.5 million; cash balance SEK 14.7 million at quarter end, later strengthened by share issue.

Outlook and guidance

• Emphasis on U.S. market adoption through focused commercial strategy, training, and partnerships.

• Strategic shift to prioritize projects with clear ROI and regulatory pathways, delaying longer-term R&D.

• Continued cost reduction efforts to extend cash runway and support growth.

• Ongoing collection of health economic evidence to support payer discussions and market access.

• Plan to enhance aftermarket business and increase sales of Axor II, with S1 surgeries as a new KPI.